Candida duobushaemulonii: an emerging rare pathogenic yeast isolated from recurrent vulvovaginal candidiasis in Brazil

Carregando...
Imagem de Miniatura
Citações na Scopus
18
Tipo de produção
article
Data de publicação
2016
Editora
FUNDACO OSWALDO CRUZ
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
BOATTO, Humberto Fabio
GIRAO, Manoel Joao B. C.
FRANCISCO, Elaine Cristina
ISHIDA, Kelly
GOMPERTZ, Olga Fischman
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
MEMORIAS DO INSTITUTO OSWALDO CRUZ, v.111, n.6, p.407-410, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The aim of this study was to identify Candida species isolated from women diagnosed with recurrent vulvovaginal candidiasis (RVVC) and their partners; and to evaluate the fluconazole (FLZ) susceptibility of the isolates. In a period of six years, among 172 patients diagnosed with vulvovaginal candidiasis, 13 women that presented RVVC and their partners were selected for this investigation. The isolates were obtained using Chromagar Candida medium, the species identification was performed by phenotypic and molecular methods and FLZ susceptibility was evaluated by E-test. Among 26 strains we identified 14 Candida albicans, six Candida duobushaemulonii, four Candida glabrata, and two Candida tropicalis. Agreement of the isolated species occurred in 100% of the couples. FLZ low susceptibility was observed for all isolates of C. duobushaemulonii (minimal inhibitory concentration values from 8-> 64 mu g/mL), two C. glabrata isolates were FLZ-resistant and all C. albicans and C. tropicalis isolates were FLZ-susceptible. This report emphasises the importance of accurate identification of the fungal agents by a reliable molecular technique in RVVC episodes besides the lower antifungal susceptibility profile of this rare pathogen C. duobushaemulonii to FLZ.
Palavras-chave
Candida duobushaemulonii, recurrent vulvovaginal candidiasis, antifungal susceptibility testing
Referências
  1. Almeida Jr JN, 2016, EMERG INFECT DIS, V22, P561
  2. Almeida Joao Nobrega de Jr, 2012, Clinics (Sao Paulo), V67, P1229
  3. Cendejas-Bueno E, 2012, J CLIN MICROBIOL, V50, P3641, DOI 10.1128/JCM.02248-12
  4. Clinical and Laboratory Standards Institute, 2012, M27S4 CLSI
  5. Giraldo PC, 2013, DST J BRAS DOENCAS S, V25, P36
  6. Khan ZU, 2007, J CLIN MICROBIOL, V45, P2025, DOI 10.1128/JCM.00222-07
  7. Kim M-N, 2009, CLIN INFECT DIS, V48, P57
  8. Kim S, 2011, J KOREAN MED SCI, V26, P297, DOI 10.3346/jkms.2011.26.2.297
  9. Kurtzman CP, 2011, YEASTS: A TAXONOMIC STUDY, VOLS 1-3, 5TH EDITION, P87, DOI 10.1016/B978-0-444-52149-1.00007-0
  10. LAVARDE V, 1984, Bulletin de la Societe Francaise de Mycologie Medicale, V13, P173
  11. LEHMANN PF, 1993, J CLIN MICROBIOL, V31, P1683
  12. Li J, 2008, CLIN INFECT DIS, V47, P1119, DOI 10.1086/592249
  13. Luo GZ, 2002, J CLIN MICROBIOL, V40, P2860, DOI 10.1128/JCM.40.8.2860-2865.2002
  14. Oberoi JK, 2012, INDIAN J MED RES, V136, P997
  15. Pappas PG, 2016, CLIN INFECT DIS, V62, pE1, DOI 10.1093/cid/civ933
  16. Ramos LS, 2015, J ANTIMICROB CHEMOTH, V70, P111, DOI 10.1093/jac/dku321
  17. Richter SS, 2005, J CLIN MICROBIOL, V43, P2155, DOI 10.1128/JCM.43.5.2155-2162.2005
  18. Rocha BA, 2008, REV SOC BRAS MED TRO, V41, P1, DOI 10.1590/S0037-86822008000100001
  19. Ruan SY, 2010, INT J ANTIMICROB AG, V35, P85, DOI 10.1016/j.ijantimicag.2009.08.009
  20. Sobel JD, 2007, LANCET, V369, P1961, DOI 10.1016/S0140-6736(07)60917-9
  21. Sobel JD, 2004, NEW ENGL J MED, V351, P876, DOI 10.1056/NEJMoa033114
  22. Taira CL, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-406
  23. White TJ, 1990, PCR PROTOCOLS GUIDE, V18, P315, DOI [DOI 10.1139/B07-071, 10.1016/b978-0-12-372180-8.50042-1]